Anti-Aβ antibody target engagement: a response to Siemers et al

Andrew D Watt, Gabriela A N Crespi, Russell A Down, David B Ascher, Adam Gunn, Keyla A Perez, Catriona A McLean, Victor L Villemagne, Michael W Parker, Kevin J Barnham, Luke A Miles

Research output: Contribution to journalComment/debatepeer-review

3 Citations (Scopus)


We have read with interest the commentary by Siemers et al. [28] regarding our paper describing the ability of the three anti-Aβ antibodies, bapineuzumab, crenezumab and solanezumab to engage Aβ in both a synthetic and a biological setting. We appreciate the opportunity to clarify any misunderstandings and here provide a brief response to their concerns.
Original languageEnglish
Pages (from-to)611-614
Number of pages4
JournalActa Neuropathologica
Issue number4
Publication statusPublished - Oct 2014
Externally publishedYes


Dive into the research topics of 'Anti-Aβ antibody target engagement: a response to Siemers et al'. Together they form a unique fingerprint.

Cite this